Stem cell therapy for knee osteoarthritis and meniscus tears is still a research field, in Japan and in the United States. The Japanese Orthopaedic Association's 2023 knee osteoarthritis guideline does not include stem cell injections among its recommendations, and the American College of Rheumatology's 2026 guideline strongly recommends against them for knee and hip osteoarthritis. In Japan, an injection of the patient's own cultured fat-derived stem cells is a Class II treatment that a clinic may offer only after filing a provision plan, and a filed plan shows that the legal procedure was followed, not that the treatment works.

This article covers why knee cartilage and the meniscus heal poorly, what researchers hope stem cells can do, how Japanese and US bodies view knee injections, the cell-based knee product Japan covers under public insurance, and what to ask before you travel.

Why knee cartilage and the meniscus heal poorly

Articular cartilage, the smooth layer covering the ends of the bones, has no blood supply and very limited ability to repair itself. The menisci are two C-shaped pads of fibrocartilage between the thigh bone and the shin bone that absorb shock and spread load. Only their outer rim has a meaningful blood supply, so tears toward the inner part are harder to heal.

Torn menisci are usually either repaired with sutures, where the tissue has a blood supply, or partly removed. Removing meniscus tissue changes how load passes through the knee and can, over time, add to the risk of osteoarthritis. That is one reason researchers want cells that could help a repaired meniscus heal.

Knee osteoarthritis is a slow wearing-down of cartilage and change in joint structure. Standard care includes exercise therapy, weight loss, medication, joint injections and, for advanced disease, surgery such as osteotomy or knee replacement.

What researchers hope stem cells can do

Knee research mostly uses mesenchymal stem cells taken from fat, bone marrow or the synovium (the joint lining). For background on these cell types, see Mesenchymal Stem Cells Explained. Researchers have two main ideas:

A person in blue scrubs holds another person's raised bare leg during an examination in a clinical room.

  • Signaling and inflammation control. The cells release a range of factors that may calm inflammation in the joint and change the environment around damaged tissue. Many researchers now think this, rather than the cells turning into new cartilage, is how they act.
  • Help with tissue repair. Cells placed at a repair site, such as a sutured meniscus, might support healing.

Both are working explanations, not settled findings. Whether cartilage actually regrows after a joint injection, how long any change in pain lasts and which patients might benefit are open questions. Studies differ widely in cell source, culture method, cell dose and disease severity, which makes them hard to compare. For the broader picture, see Does Stem Cell Therapy Work?.

How Japanese and US guidelines view knee injections

Japan. The Japanese Orthopaedic Association's Clinical Practice Guideline for Knee Osteoarthritis 2023 sets out clinical questions on education, exercise, weight loss, physical therapy, bracing, drugs, hyaluronic acid and steroid injections, and arthroscopic surgery. Stem cell injections are not among them.

The guideline does include a separate evidence review of platelet-rich plasma (PRP), because patients often ask about it in clinic. Its committee pooled randomized trials comparing PRP with saline and concluded:

  • Results for pain relief, physical function and daily living or quality of life varied too much between studies to allow a reliable judgment of effect.
  • Safety could not be reliably judged either.
  • The analysis did not show an effect on cartilage repair or regeneration.

The same review notes that PRP injected into a joint does not count as homologous use, so it is a Class II technique under Japan's regenerative medicine law. It also cites the Japan Agency for Medical Research and Development (AMED), which says that because such treatments are offered as self-paid care, rigorous clinical studies first need work on standardizing the treatment, quality testing of processed cells, narrowing down suitable patients and choosing proper outcome measures. PRP is not a stem cell treatment, but the review shows how Japanese orthopedic specialists view regenerative knee injections: the evidence is not yet strong enough to draw conclusions. More on PRP is in PRP Therapy Explained.

United States. The FDA states that regenerative medicine therapies have not been approved for any orthopedic condition, including osteoarthritis, and that the only FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood, used for disorders of blood production. In September 2026, the American College of Rheumatology published an updated osteoarthritis guideline that strongly recommends against PRP and stem cell injections for knee and hip osteoarthritis, according to Healio's report on the guideline.

Japanese research: synovial stem cells for the meniscus

Japan has run formal clinical studies on the meniscus. A team led by Ichiro Sekiya at Tokyo Medical and Dental University studied the patient's own synovial mesenchymal stem cells to promote meniscus healing. According to the team's AMED report for fiscal 2015:

  • In a study of synovial stem cell transplantation after meniscus repair, the planned 5 transplants were completed between August and November 2014.
  • A second study, in meniscus injuries with extrusion (the meniscus slipping out of place), was approved after review by the university's specially certified regenerative medicine committee under the Safety Act. Its planned 10 transplants were completed between August and December 2015.
  • As of the end of fiscal 2015, no serious adverse events had occurred in either study. The team had signed a joint research agreement with a licensee company and aimed to file a clinical trial notification in fiscal 2016.

These were small early studies focused mainly on safety, not on how much the procedure helps patients.

The insurance-covered option is cultured cartilage, not stem cells

A different product is often mixed up with stem cell injections: the autologous cultured cartilage ジャック (Jack), made by Japan Tissue Engineering Co., Ltd. (J-TEC). According to Hiroshima University's January 2026 press materials, which include J-TEC's release:

Person in a white coat holding up a knee X-ray film

  • It is made from the patient's own healthy knee cartilage cells, cultured for about four weeks in a gel and implanted into the cartilage defect in surgery, covered and fixed with a membrane (an artificial collagen membrane or periosteum).
  • It was approved in July 2012 for traumatic cartilage defects and osteochondritis dissecans and came to market in April 2013.
  • J-TEC received approval to add knee osteoarthritis in May 2025, and public insurance coverage for that use started on 1 January 2026. Eligible patients are those whose symptoms have not improved with conservative treatment such as exercise therapy and who have a cartilage defect of 2 cm² or more, with enough surrounding cartilage to suture the cover.
  • The osteoarthritis approval followed a multicenter randomized trial, begun in 2019, that compared it with hyaluronic acid joint injections.

It differs from a clinic stem cell injection in three ways: it uses cartilage cells rather than stem cells; it is implanted surgically rather than injected into the joint; and it is an approved regenerative medicine product used within its approved conditions under public insurance.

The closest US parallel is MACI (autologous cultured chondrocytes on porcine collagen membrane), made by Vericel Corporation. The FDA lists it for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. Like ジャック, it is a surgically implanted product made from the patient's own cartilage cells, not a stem cell injection.

How Japan classifies a knee stem cell injection

Knee stem cell injections offered by Japanese clinics as self-paid care usually use the patient's own fat-derived stem cells: a small amount of fat is taken, typically from the abdomen, the cells are isolated and cultured in a cell processing facility, and they are then injected into the knee. At the institutions we work with, an autologous adipose-derived stem cell course typically runs about 6 to 12 months, with regular trips to Japan; the doctor sets the actual plan.

Approach Class under the Safety Act Legal basis
Patient's own cultured stem cells (fat, bone marrow, synovium) Class II Enforcement Regulations, Art. 3, item 1
Cells from someone other than the patient (e.g. donated umbilical cord cells) Class I Enforcement Regulations, Art. 2, item 4
PRP injected into the joint Class II (non-homologous use) Enforcement Regulations, Art. 3, item 3; JOA guideline 2023

Before offering any of these, the clinic must file a provision plan through the e-Saisei system after review by a certified committee. For Class I, the Act gives the Minister of Health, Labour and Welfare 90 days after filing to order changes, and the treatment may not be provided until that period ends. The class of a specific treatment is the one in the clinic's filed plan. The full framework is in Regenerative Medicine in Japan: How the Safety Act Works and How Japan regulates regenerative medicine.

These clinic treatments are self-paid and outside Japan's public health insurance. Costs are usually made up of the initial consultation and tests, fat collection, cell culture and processing, the injections and follow-up visits; each institution sets its own fees, and an advisor gives you a quote from the specific hospital. See How Much Does Stem Cell Therapy Cost in Japan? for the components.

Realistic expectations

  • What you can expect from a compliant provider: a clear explanation of the treatment's class, the reviewing committee, the risks and how results will be assessed. Responses vary widely, and there are no reliable data on who benefits or for how long.
  • Claims to treat with caution: "cartilage regrowth," "no need for a knee replacement" or "results after one shot" lack reliable human evidence. For advanced osteoarthritis with clear joint deformity, osteotomy or knee replacement remain the main orthopedic options.
  • Risks: pain and bruising where fat is taken; swelling and pain in the knee after injection; and, less often but importantly, infection. How the cells are cultured and transported also affects safety.

Questions to ask before you travel

  1. Which class is this treatment, and which certified committee reviewed it?
  2. Where do the cells come from: my own body or a donor? Are they cultured?
  3. Where are the cells processed, how long from collection to injection, and how many trips to Japan will I need?
  4. How will results be measured before and after, and is there long-term follow-up?
  5. What does the fee cover, and how are extra injections charged?

MRI scan of a knee displayed on a monitor with crosshair and measurement markers

For knee osteoarthritis, our advisors can arrange a consultation with a Japanese doctor directly, including record translation, a remote video consultation, an interpreter throughout and follow-up after you return home. Consultation and coordination are free, and we reply within one working day. Clients who travel with our coordination usually enter Japan for a short-term stay and handle their own visa; an advisor tells you what to prepare. If you already have a clinic in mind, send its name to our advisors and we will check whether it has filed a provision plan. Start with our Pre-screening, and see Getting treated in Japan for the steps.

Frequently asked questions

Can stem cells regrow knee cartilage?

There is no reliable evidence that they do. Study results on cartilage regrowth after joint injection are inconsistent, and many researchers think the cells act mainly by releasing factors that affect inflammation.

Can stem cells replace surgery for a meniscus tear?

No; in the Japanese research they were used alongside surgery. The synovial stem cell studies transplanted cells after meniscus repair to support healing, and they were small early-stage studies.

What class is a fat-derived stem cell knee injection in Japan?

It is generally Class II when the patient's own cultured stem cells are used. If donor cells such as umbilical cord cells are used, it is Class I. The class of a specific treatment is the one in the clinic's filed plan.

Is stem cell therapy for knees FDA-approved?

No. The FDA states that regenerative medicine therapies have not been approved for any orthopedic condition, including osteoarthritis. The FDA-approved knee cartilage product MACI uses cultured cartilage cells implanted in surgery, not stem cells.

What knee cell therapy does Japanese public insurance cover?

It covers the cultured cartilage product ジャック, made from the patient's own cartilage cells and implanted surgically. Since 1 January 2026, coverage includes eligible knee osteoarthritis patients. It is not a stem cell injection.

Sources: Japanese Orthopaedic Association, Clinical Practice Guideline for Knee Osteoarthritis 2023 and its reference material 2 on PRP; AMED fiscal 2015 research report "Meniscus regeneration with synovial stem cells"; Hiroshima University press materials of 29 January 2026 with J-TEC's 22 January 2026 release; Act on the Safety of Regenerative Medicine and its Enforcement Regulations, current text via the e-Gov law database; MHLW page on regenerative medicine, cell therapy and gene therapy; FDA consumer information on regenerative medicine therapies and FDA product information for MACI; Healio report of 14 September 2026 on the ACR osteoarthritis guideline. Checked November 2026; MHLW and FDA publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.